ATC and PTC diverge early in tumor development
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB24697 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR2275120.fastq.gz | Fastqsanger.gz | |||
| ERR2275120_1.fastq.gz | Fastqsanger.gz | |||
| ERR2275120_2.fastq.gz | Fastqsanger.gz | |||
| ERR2275130.fastq.gz | Fastqsanger.gz | |||
| ERR2275130_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 93 |
Similar Datasets
Project description:The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with very high mortality. Double-stranded RNA–directed RNA interference (dsRNAi) targeting the PIAS2 isoform beta (PIAS2b) inhibits growth of ATC cell lines and patient primary cultures in vitro and orthotopic patient-derived xenografts (oPDX) in vivo, but not of thyroid cell lines or non-anaplastic primary thyroid cultures (differentiated carcinoma, benign lesions, or normal). PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. Strikingly, PIAS2b-dsRNAi induces mitotic catastrophe at prophase. High-throughput proteomics revealed the proteasome (PSMC5) and spindle cytoskeleton as direct targets of PIAS2b SUMOylation at mitotic initiation. PIAS2b-dsRNAi is a promising therapy for ATC and other aggressive anaplastic cancers.
2024-04-08 | PXD044110 | Pride
Project description:We profiled the gene expression of anaplastic thyroid cancers of Belgian patients. We compared these with the expression profile of a cohort of papillary thyroid tumors both from the Chernobyl Tissues Bank (CTB) and French patients with no history of exposure to radiations, along with their patient-matched healthy adjacent thyroid.
2012-06-01 | GSE29265 | GEO
Project description:Sporadic vs. Post-Chernobyl Papillary vs. Anaplastic Thyroid Cancers
| PRJNA140273 | ENA
Project description:We profiled the gene expression of 11 anaplastic thyroid carcinomas (ATC), 49 papillary thyroid carcinomas (PTC) and 45 normal thyroids (N) We hibridized a series of anaplastic thyroid carcinomas (ATC) and papillary thyroid carcinomas (PTC) onto Affymetrix U133 Plus 2.0 arrays. ATCs were obtained from different hospitals in France and Belgium. Paired RNA samples of PTCs and non-tumoral thyroid tissues were obtained from Ukraine via the Chernobyl Tissue Bank (www.chernobyltissuebank.com). Diagnoses were confirmed by the members of the International Pathology Panel of the Chernobyl Tissue Bank.
2012-11-09 | E-GEOD-33630 | biostudies-arrayexpress
Project description:We profiled the gene expression of 11 anaplastic thyroid carcinomas (ATC), 49 papillary thyroid carcinomas (PTC) and 45 normal thyroids (N)
2012-11-09 | GSE33630 | GEO
Project description:Higher CD47 expression in some cancers correlates with poor survival. In contrast, higher CD47 mRNA expression in papillary thyroid carcinomas correlated with significantly improved overall survival. IFT57 was the top gene coexpressed with CD47 in these tumors, and higher IFT57 mRNA correlated with significantly improved overall and disease-free survival. IFT57 is a component of the primary cilium, which also regulates cancer pathogenesis. IFT57 and CD47 are colinear genes in humans, and this synteny is highly conserved across amniote genomes. Transcriptional regulators have been identified that increase CD47 expression in cancers, but its proximity suggested that IFT57 could be coregulated. CD47 and IFT57 mRNAs were also coregulated in anaplastic thyroid carcinoma cell lines and carcinomas of multiple tissues. Anaplastic thyroid carcinoma cell line mutants with decreased IFT57 or CD47 expression were used to define IFT57-dependent phenotypes and gene expression. Loss of IFT57 expression regulated transcripts involved in cell motility and extracellular matrix pathways. Altered cell motility was confirmed in IFT57 mutants. Three IFT57-dependent genes identified in the cell lines exhibited stronger coexpression with IFT57 than with CD47 in papillary thyroid tumors. CRACD was identified as an IFT57-specific target that correlates with survival in lung as well as papillary thyroid carcinomas.
2024-09-13 | GSE254982 | GEO
Project description:To investigate the effects of combined BRAF inhibition (dabrafenib) and ERK inhibition (ulixertinib) on papillary and anaplastic thyroid cancer transcriptional reprogramming
2023-06-15 | GSE221329 | GEO
Project description:Anaplastic thyroid carcinoma (ATC) has among the worst prognosis of any solid malignancy. The low incidence of the disease has in part precluded systematic clinical trials and tissue collection, and there has been little progress in developing effective therapies. BRAF and TP53 mutations co-occur in a high proportion of ATC, particularly those associated with a precursor papillary thyroid carcinoma (PTC). In order to develop an adult-onset model of BRAF-mutant anaplastic thyroid carcinoma, we generated a novel thyroid-specific CreER transgenic mouse. We utilize a Cre-regulated BrafV600E mouse and a conditional Trp53 allelic series to demonstrate that p53 constrains progression from papillary to anaplastic thyroid carcinoma. Gene expression and immunohistochemical analyses of murine tumors identified the cardinal features of human ATC including loss of differentiation, local invasion, distant metastasis and rapid lethality. We employed small animal ultrasound imaging to monitor autochthonous tumors, and show that treatment with the selective BRAF inhibitor PLX4720 improved survival, but did not lead to tumor regression or suppress signaling through the MAPK pathway. Combination of PLX4720 and the MEK inhibitor PD0325901 more completely suppressed MAPK pathway activation in mouse and human ATC cell lines, and improved the structural response and survival of ATC-bearing animals. This model expands the limited repertoire of autochthonous models of clinically aggressive thyroid cancer, and these data suggest that small molecule MAPK pathway inhibitors hold clinical promise in the treatment of advanced thyroid carcinoma. Total RNA from five murine papillary thyroid carcinoma (PTC) tumors and five murine anaplastic thyroid carcinoma (ATC) tumors was analyzed.
2014-04-02 | E-GEOD-55933 | biostudies-arrayexpress
Project description:A comparison of profiles of normal thryoid tissue (NT), papillary thyroid carcinoma tissue (PTC) and anaplastic thyroid carcinoma tissue (ATC) was carried out to identify expression patterns specifically associated with analplastic thyroid carcinoma Keywords: Expression profile survey of normal tissue and tumor subtypes
2007-09-21 | GSE9115 | GEO
Project description:Purpose: The primary goal of this study was to identify gene-expression profiles of anaplastic thyroid cancer and to identify some novel in-frame gene fusions that could result in translated protein products affecting the development of anaplastic thyroid cancer. Methods: RNAseq Data was processed with TCGA UNC V2 RNAseq protocol and different expressed genes were identify by using DESeq2, limma-voom, and edgeR. Potential fusion genes were identified by using SOAPfuse, Chimerascan and TopHat-Fusion. Potential fusion genes were confirmed by cDNA PCR and Sanger sequencing. Results: A total of 21 fusion genes were detected, including six predicted in-frame fusions; none were recurrent. Global gene expression analysis showed 661 genes to be differentially expressed between anaplastic thyroid cancer and papillary thyroid cancer cell lines, with pathway enrichment analyses showing downregulation of TP53-signaling as well as cell adhesion molecules in anaplastic thyroid cancer . Conclusions: Our study represents the first detailed analysis of anaplastic thyroid cancer cell lines and found several novel in-frame gene fusions that could result in translated protein products affecting the development of anaplastic thyroid cancer. These data provide novel insights into the tumorigenesis of anaplastic thyroid cancer and may be used to identify new therapeutic targets.
2017-05-08 | GSE94464 | GEO